1. Home
  2. AVDL vs KALV Comparison

AVDL vs KALV Comparison

Compare AVDL & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Avadel Pharmaceuticals plc

AVDL

Avadel Pharmaceuticals plc

HOLD

Current Price

$21.39

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

HOLD

Current Price

$17.00

Market Cap

551.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AVDL
KALV
Founded
2015
N/A
Country
Ireland
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
551.2M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
AVDL
KALV
Price
$21.39
$17.00
Analyst Decision
Buy
Strong Buy
Analyst Count
9
8
Target Price
$18.38
$26.43
AVG Volume (30 Days)
2.8M
1.6M
Earning Date
11-04-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$248,517,000.00
$1,426,000.00
Revenue This Year
$65.47
N/A
Revenue Next Year
$30.88
$204.16
P/E Ratio
N/A
N/A
Revenue Growth
79.88
N/A
52 Week Low
$6.38
$7.30
52 Week High
$23.57
$17.28

Technical Indicators

Market Signals
Indicator
AVDL
KALV
Relative Strength Index (RSI) 58.68 70.46
Support Level $21.29 $15.88
Resistance Level $21.55 $17.10
Average True Range (ATR) 0.25 1.08
MACD -0.26 0.22
Stochastic Oscillator 9.50 96.52

Price Performance

Historical Comparison
AVDL
KALV

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

Share on Social Networks: